Business Wire

IFPMA

19.7.2022 14:02:11 CEST | Business Wire | Press release

Share
Pharma Proposes to Work with G7 and G20 on a Joint Solution for Better Access to Vaccines and Treatments Around the World for Future Pandemics

The biopharmaceutical industry launched today the “Berlin Declaration – biopharmaceutical industry vision for equitable access in pandemics ” and presents global leaders with a proposal that could help ensure the supply of pandemic vaccines, treatments and diagnostics are delivered as early as possible in future pandemics to those who need them most. The industry, which developed COVID-19 vaccines and treatments at record speed and in historic quantities, proposes to create a collaborative solution for the even more equitable rollout of vaccines, treatments and diagnostics for future pandemics. It is tabling the declaration and calling for discussions with G7, G20, multilateral organizations and other decision-makers involved in pandemic preparedness to explore how industry’s offer to prioritize and reserve an allocation of real-time production for distribution to priority populations in lower-income countries would contribute towards the holistic and equitable solution the world needs.

A prerequisite for the declaration to succeed is to ensure that health systems in lower income countries are better prepared to absorb and deliver vaccines and treatments, and for high income countries to provide the necessary political and financial support. The declaration underscores the necessity for a strong innovation eco-system, grounded in intellectual property rights, and the removal of trade and regulatory barriers to export. It also emphasizes that without robust pandemic plans to deliver pandemic vaccines, treatments and diagnostics and care to populations in all countries, attempts to improve equity will falter.

The declaration is an acknowledgement that while innovation and manufacturing scaling succeeded in an unprecedented way during COVID-19, efforts to achieve equitable access were not fully realized because of inadequate financing mechanisms upfront and a lack of country readiness which still inhibits the vaccines from getting to every arm that needs it. For future pandemics, it is critical to ensure that all countries have the technical and health infrastructure, human resources and financial capacity as well as political support to successfully vaccinate, test and care for their populations. Furthermore, the success of the proposal requires open borders and no trade restrictions.

The June G7 summit outcomes (link ) relating to investing in a better future for health under the overarching theme of “progress towards an equitable world”, and the recently approved the Pandemic Financial Intermediary Fund (link ) are encouraging signs that the world has not moved as is feared from panic to neglect when it comes to preparing for future pandemics. Jean-Christophe Tellier, IFPMA President and CEO of UCB, said “we applaud Germany’s leadership of the G7’s pandemic response and trust that our declaration is seen by world leaders as a practical proposal to build greater equitable access into future pandemic response. For this potentially life-saving concept to become reality, we will need to work with G7, and later this year in Bali with G20 to flesh out how to make it work. The reward if successful will help shape a future where everyone has a chance to be better protected from the threat of pandemics from the outset, no matter where they live”.

The industry is already receiving positive reactions to its proposal, and expressions of interest to take the discussion further.

His Excellency Budi Gunadi Sadikin, Minister of Health of Indonesia said: “The biopharmaceutical industry has a critical role to play in preparing for future pandemics. Achieving more equitable access to vaccines and treatments in future pandemics will require close collaboration of governments, private sector and civil society. I welcome the biopharmaceutical industry’s commitment to our shared vision for ‘real-time’ access to priority populations in lower income countries. I look forward to working with political leaders in the G7 and G20 to advance this important initiative.”

José Manuel Barroso, Gavi Chair and COVAX co-Chair shared his insights on hearing about the proposal: “I applaud IFPMA and industry leaders for seizing the initiative. We saw effective innovation and manufacturing scaling up with this pandemic; but we also saw the challenges we had to overcome to get the vaccines to all those who needed them. The industry’s commitment to reserve part of production of vaccines and treatments at real time for vulnerable populations in low-income countries provides an opportunity to work together strategically to forge a new social contract. I hope that political leaders will do their part and engage with industry on how to make this work.”

The body representing industry towards the multilateral institutions throughout the COVID-19 pandemic, IFPMA, will be taking the proposal forwards to the G7 and G20. Thomas Cueni, Director General of IFPMA: “With all stakeholders collaborating and playing their part, we can make sure that the efforts, investments, learnings and losses seen during COVID-19 are not in vain, but rather help shape a future where everyone is better protected from the threat of pandemics. While we have been developing the declaration, I have been very encouraged by the positive responses we have received from government officials as well as partners and civil society. Our proposal is just a first step along the way to what I believe has the potential to be a transformational solution for future pandemics.”

ABOUT

IFPMA (https://www.ifpma.org/ ) represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees discover, develop, and deliver medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release

On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con

ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release

ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer

Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release

Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population

Adyen Merchants Can Now Offer Klarna in AI Agent Checkout20.11.2026 14:30:00 CET | Press release

Klarna is Adyen’s first non-card, local payment method for agentic commerce Klarna (NYSE: KLAR), the everyday finance network, and Adyen (AMS: ADYEN) today announced that shoppers can now pay with Klarna when an AI agent checks out for them through Adyen Agentic. Klarna is the first payment option beyond cards available in Adyen Agentic, Adyen’s agentic commerce suite, and merchants that already offer Klarna through Adyen can switch it on with no new integration work. Today, most AI shopping agents complete purchases with a stored credit or debit card, leaving out flexible payment options that many shoppers choose at regular checkout. With Klarna now a payment method within Adyen Agentic, the agent shows shoppers the same Klarna options the merchant already offers, such as paying in full, in interest-free installments or with financing. Shoppers review and confirm every purchase before it is completed. Adyen built the integration on Klarna’s open payment handler, a published specificat

SatSure Raises Series B to Scale Its Full-Stack Earth Intelligence Platform for Global Markets20.11.2026 11:05:00 CET | Press release

India’s sovereign space-technology fund leads the first close of the ongoing INR 200 crore (c. USD 21 million) round SatSure, a global Earth intelligence company headquartered in India, today announced the first close of its ongoing INR 200 crore (c. USD 21 million) Series B round. The round is led by a INR 60 crore (c. USD 6.4 million) investment from the Antariksh Venture Capital Fund (AVCF), India’s sovereign space-technology fund, anchored by the national space regulator IN-SPACe and managed by SIDBI Venture Capital Limited. The investment marks AVCF’s first deployment into the downstream data and AI layer of India’s space economy, extending the fund beyond upstream launch and satellite hardware into commercial space-data infrastructure capable of serving global enterprise and sovereign markets. The round comprises INR 165 crore (c. USD 17.6 million) in equity, INR 25 crore (c. USD 2.7 million) in venture debt and INR 10 crore (c. USD 1.1 million) in secondary transactions, closing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye